BG104048A - Състав съдържащ 5-/4-/2-(n-метил-n-2-пиридил) амино)- етокси/ бензин/ тиазолидин-2,4-дион - Google Patents

Състав съдържащ 5-/4-/2-(n-метил-n-2-пиридил) амино)- етокси/ бензин/ тиазолидин-2,4-дион Download PDF

Info

Publication number: BG104048A
Authority: BG; Bulgaria
Prior art keywords: pharmaceutically acceptable; compound; composition; acceptable form; acceptable carrier
Prior art date: 1997-06-05

Application number

BG104048A

Other languages

Bulgarian (bg)

English (en)

Inventor

Jai Patel

Hamish Ross

Jeffrey Granett

Robin Price

Paul WRAY

Original Assignee

Smithkline Beecham P.L.C.

Smithkline Beecham Corporation

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-06-05

Filing date

1999-12-27

Publication date

2000-07-31

1997-06-18 Priority claimed from GBGB9712851.6A external-priority patent/GB9712851D0/en

1999-12-27 Application filed by Smithkline Beecham P.L.C., Smithkline Beecham Corporation filed Critical Smithkline Beecham P.L.C.

2000-07-31 Publication of BG104048A publication Critical patent/BG104048A/bg

Links

239000000203 mixture Substances 0.000 title claims abstract description 98
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 title 1
150000001875 compounds Chemical class 0.000 claims abstract description 93
238000000034 method Methods 0.000 claims abstract description 39
239000003937 drug carrier Substances 0.000 claims abstract description 21
239000008194 pharmaceutical composition Substances 0.000 claims description 14
239000012141 concentrate Substances 0.000 claims description 12
238000009472 formulation Methods 0.000 claims description 12
150000003839 salts Chemical class 0.000 claims description 11
239000002552 dosage form Substances 0.000 claims description 9
229920000168 Microcrystalline cellulose Polymers 0.000 claims description 8
235000019813 microcrystalline cellulose Nutrition 0.000 claims description 8
239000008108 microcrystalline cellulose Substances 0.000 claims description 8
229940016286 microcrystalline cellulose Drugs 0.000 claims description 8
238000002156 mixing Methods 0.000 claims description 7
WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 claims description 6
229960001021 lactose monohydrate Drugs 0.000 claims description 6
229920003109 sodium starch glycolate Polymers 0.000 claims description 5
239000008109 sodium starch glycolate Substances 0.000 claims description 5
229940079832 sodium starch glycolate Drugs 0.000 claims description 5
229940031705 hydroxypropyl methylcellulose 2910 Drugs 0.000 claims description 4
238000010790 dilution Methods 0.000 claims description 3
239000012895 dilution Substances 0.000 claims description 3
YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 claims description 2
239000003814 drug Substances 0.000 abstract description 3
239000003826 tablet Substances 0.000 description 15
208000001072 type 2 diabetes mellitus Diseases 0.000 description 12
206010012601 diabetes mellitus Diseases 0.000 description 11
238000002360 preparation method Methods 0.000 description 11
235000008504 concentrate Nutrition 0.000 description 10
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical group [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
206010022489 Insulin Resistance Diseases 0.000 description 5
239000008187 granular material Substances 0.000 description 5
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
239000007884 disintegrant Substances 0.000 description 4
229960001375 lactose Drugs 0.000 description 4
239000008101 lactose Substances 0.000 description 4
239000000314 lubricant Substances 0.000 description 4
235000019359 magnesium stearate Nutrition 0.000 description 4
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
239000011230 binding agent Substances 0.000 description 3
239000003085 diluting agent Substances 0.000 description 3
239000000945 filler Substances 0.000 description 3
238000011049 filling Methods 0.000 description 3
239000004615 ingredient Substances 0.000 description 3
239000007788 liquid Substances 0.000 description 3
239000000546 pharmaceutical excipient Substances 0.000 description 3
229940080313 sodium starch Drugs 0.000 description 3
239000000600 sorbitol Substances 0.000 description 3
235000010356 sorbitol Nutrition 0.000 description 3
239000000725 suspension Substances 0.000 description 3
235000020357 syrup Nutrition 0.000 description 3
239000006188 syrup Substances 0.000 description 3
-1 thiazolidinedione compound Chemical class 0.000 description 3
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 3
108010010803 Gelatin Proteins 0.000 description 2
206010018429 Glucose tolerance impaired Diseases 0.000 description 2
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
235000010643 Leucaena leucocephala Nutrition 0.000 description 2
240000007472 Leucaena leucocephala Species 0.000 description 2
208000008589 Obesity Diseases 0.000 description 2
239000004480 active ingredient Substances 0.000 description 2
239000013543 active substance Substances 0.000 description 2
239000002775 capsule Substances 0.000 description 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
208000035475 disorder Diseases 0.000 description 2
239000008157 edible vegetable oil Substances 0.000 description 2
238000001914 filtration Methods 0.000 description 2
239000008273 gelatin Substances 0.000 description 2
229920000159 gelatin Polymers 0.000 description 2
235000019322 gelatine Nutrition 0.000 description 2
235000011852 gelatine desserts Nutrition 0.000 description 2
208000017169 kidney disease Diseases 0.000 description 2
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
229920000609 methyl cellulose Polymers 0.000 description 2
239000001923 methylcellulose Substances 0.000 description 2
235000010981 methylcellulose Nutrition 0.000 description 2
235000020824 obesity Nutrition 0.000 description 2
238000007911 parenteral administration Methods 0.000 description 2
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
239000001267 polyvinylpyrrolidone Substances 0.000 description 2
229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
239000000843 powder Substances 0.000 description 2
239000003755 preservative agent Substances 0.000 description 2
239000008213 purified water Substances 0.000 description 2
239000007787 solid Substances 0.000 description 2
239000003981 vehicle Substances 0.000 description 2
239000000080 wetting agent Substances 0.000 description 2
ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 1
IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
235000019489 Almond oil Nutrition 0.000 description 1
208000000103 Anorexia Nervosa Diseases 0.000 description 1
206010003497 Asphyxia Diseases 0.000 description 1
241000416162 Astragalus gummifer Species 0.000 description 1
201000001320 Atherosclerosis Diseases 0.000 description 1
208000032841 Bulimia Diseases 0.000 description 1
206010006550 Bulimia nervosa Diseases 0.000 description 1
229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
208000024172 Cardiovascular disease Diseases 0.000 description 1
229920002261 Corn starch Polymers 0.000 description 1
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
208000002249 Diabetes Complications Diseases 0.000 description 1
208000032131 Diabetic Neuropathies Diseases 0.000 description 1
208000030814 Eating disease Diseases 0.000 description 1
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical class CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
208000019454 Feeding and Eating disease Diseases 0.000 description 1
206010018364 Glomerulonephritis Diseases 0.000 description 1
208000002705 Glucose Intolerance Diseases 0.000 description 1
239000004471 Glycine Substances 0.000 description 1
239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
206010060378 Hyperinsulinaemia Diseases 0.000 description 1
206010020710 Hyperphagia Diseases 0.000 description 1
206010020772 Hypertension Diseases 0.000 description 1
208000002720 Malnutrition Diseases 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
206010036049 Polycystic ovaries Diseases 0.000 description 1
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
229940123464 Thiazolidinedione Drugs 0.000 description 1
229920001615 Tragacanth Polymers 0.000 description 1
239000002253 acid Substances 0.000 description 1
239000000654 additive Substances 0.000 description 1
239000008168 almond oil Substances 0.000 description 1
CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
229940063655 aluminum stearate Drugs 0.000 description 1
229940035674 anesthetics Drugs 0.000 description 1
208000022531 anorexia Diseases 0.000 description 1
235000021229 appetite regulation Nutrition 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
239000000872 buffer Substances 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
229910052799 carbon Inorganic materials 0.000 description 1
125000004432 carbon atom Chemical group C* 0.000 description 1
239000001768 carboxy methyl cellulose Substances 0.000 description 1
235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
239000008112 carboxymethyl-cellulose Substances 0.000 description 1
235000010980 cellulose Nutrition 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
208000020832 chronic kidney disease Diseases 0.000 description 1
239000003240 coconut oil Substances 0.000 description 1
235000019864 coconut oil Nutrition 0.000 description 1
239000003086 colorant Substances 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
239000008120 corn starch Substances 0.000 description 1
206010061428 decreased appetite Diseases 0.000 description 1
235000014632 disordered eating Nutrition 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
208000028208 end stage renal disease Diseases 0.000 description 1
201000000523 end stage renal failure Diseases 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
238000009501 film coating Methods 0.000 description 1
239000007888 film coating Substances 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
239000012530 fluid Substances 0.000 description 1
230000037406 food intake Effects 0.000 description 1
235000012631 food intake Nutrition 0.000 description 1
239000013022 formulation composition Substances 0.000 description 1
239000000499 gel Substances 0.000 description 1
239000003193 general anesthetic agent Substances 0.000 description 1
208000004104 gestational diabetes Diseases 0.000 description 1
206010061989 glomerulosclerosis Diseases 0.000 description 1
230000002641 glycemic effect Effects 0.000 description 1
150000004677 hydrates Chemical class 0.000 description 1
235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
230000000055 hyoplipidemic effect Effects 0.000 description 1
230000003345 hyperglycaemic effect Effects 0.000 description 1
230000003451 hyperinsulinaemic effect Effects 0.000 description 1
201000008980 hyperinsulinism Diseases 0.000 description 1
230000002218 hypoglycaemic effect Effects 0.000 description 1
235000010445 lecithin Nutrition 0.000 description 1
239000000787 lecithin Substances 0.000 description 1
229940067606 lecithin Drugs 0.000 description 1
150000002688 maleic acid derivatives Chemical class 0.000 description 1
230000001071 malnutrition Effects 0.000 description 1
235000000824 malnutrition Nutrition 0.000 description 1
239000000463 material Substances 0.000 description 1
FJQXCDYVZAHXNS-UHFFFAOYSA-N methadone hydrochloride Chemical compound Cl.C=1C=CC=CC=1C(CC(C)N(C)C)(C(=O)CC)C1=CC=CC=C1 FJQXCDYVZAHXNS-UHFFFAOYSA-N 0.000 description 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
239000002687 nonaqueous vehicle Substances 0.000 description 1
208000015380 nutritional deficiency disease Diseases 0.000 description 1
239000003182 parenteral nutrition solution Substances 0.000 description 1
235000010603 pastilles Nutrition 0.000 description 1
201000010065 polycystic ovary syndrome Diseases 0.000 description 1
201000009104 prediabetes syndrome Diseases 0.000 description 1
239000000047 product Substances 0.000 description 1
235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
235000019333 sodium laurylsulphate Nutrition 0.000 description 1
239000000243 solution Substances 0.000 description 1
239000012453 solvate Substances 0.000 description 1
239000001593 sorbitan monooleate Substances 0.000 description 1
235000011069 sorbitan monooleate Nutrition 0.000 description 1
229940035049 sorbitan monooleate Drugs 0.000 description 1
229940032147 starch Drugs 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
230000001954 sterilising effect Effects 0.000 description 1
238000004659 sterilization and disinfection Methods 0.000 description 1
150000003431 steroids Chemical class 0.000 description 1
239000013589 supplement Substances 0.000 description 1
239000000829 suppository Substances 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
208000011580 syndromic disease Diseases 0.000 description 1
238000009492 tablet coating Methods 0.000 description 1
239000002700 tablet coating Substances 0.000 description 1
150000001467 thiazolidinediones Chemical class 0.000 description 1
230000002110 toxicologic effect Effects 0.000 description 1
231100000759 toxicological effect Toxicity 0.000 description 1
239000000196 tragacanth Substances 0.000 description 1
235000010487 tragacanth Nutrition 0.000 description 1
229940116362 tragacanth Drugs 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
238000009827 uniform distribution Methods 0.000 description 1
239000008215 water for injection Substances 0.000 description 1
238000005550 wet granulation Methods 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Diabetes (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Hematology (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Obesity (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Endocrinology (AREA)
Emergency Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Medicinal Preparation (AREA)

BG104048A 1997-06-05 1999-12-27 Състав съдържащ 5-/4-/2-(n-метил-n-2-пиридил) амино)- етокси/ бензин/ тиазолидин-2,4-дион BG104048A (bg)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
GBGB9711683.4A GB9711683D0 (en)	1997-06-05	1997-06-05	Composition
GBGB9712851.6A GB9712851D0 (en)	1997-06-18	1997-06-18	Composition
PCT/EP1998/003478 WO1998055122A1 (en)	1997-06-05	1998-06-02	Composition comprising 5-[4-[2-(n-methyl-n-2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione

Publications (1)

Publication Number	Publication Date
BG104048A true BG104048A (bg)	2000-07-31

Family

ID=26311662

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BG104048A BG104048A (bg)	1997-06-05	1999-12-27	Състав съдържащ 5-/4-/2-(n-метил-n-2-пиридил) амино)- етокси/ бензин/ тиазолидин-2,4-дион

Country Status (29)

Country	Link
EP (1)	EP0998284A1 (id)
JP (1)	JP2001521553A (id)
KR (1)	KR20010013410A (id)
CN (3)	CN1112926C (id)
AP (1)	AP1214A (id)
AR (2)	AR008198A1 (id)
AU (1)	AU8215098A (id)
BG (1)	BG104048A (id)
BR (1)	BR9810405A (id)
CA (2)	CA2333352A1 (id)
CO (1)	CO4940400A1 (id)
DZ (1)	DZ2510A1 (id)
EA (1)	EA002384B1 (id)
GB (1)	GB9711683D0 (id)
HU (1)	HUP0004070A3 (id)
ID (1)	ID24264A (id)
IL (1)	IL133074A0 (id)
MX (1)	MXPA99011322A (id)
NO (2)	NO995938L (id)
NZ (2)	NZ523725A (id)
OA (1)	OA11306A (id)
PE (1)	PE78899A1 (id)
PL (1)	PL337201A1 (id)
SK (1)	SK164899A3 (id)
TR (2)	TR200002790T2 (id)
TW (1)	TW570797B (id)
UY (1)	UY25032A1 (id)
WO (1)	WO1998055122A1 (id)
ZA (2)	ZA984826B (id)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7045519B2 (en)	1998-06-19	2006-05-16	Chiron Corporation	Inhibitors of glycogen synthase kinase 3
US20040248945A1 (en)	1999-04-23	2004-12-09	Smithkline Beecham P.L.C.	Thiazolidinedione derivative and its use as antidiabetic
AR023561A1 (es) *	1999-04-23	2002-09-04	Smithkline Beecham Corp	Una forma polimorfica del acido maleico de un derivado de tiazolidin-2, 4 diona, una composicion farmaceutica y el uso de dicho polimorfo para lafabricacion de un medicamento
HRP20010773B1 (en)	1999-04-23	2005-06-30	Smithkline Beecham P.L.C.	Thiazolidinedione derivative and its use as antidiabetic
GB0021978D0 (en)	2000-09-07	2000-10-25	Smithkline Beecham Plc	Novel pharmaceutical
GB0127805D0 (en) *	2001-11-20	2002-01-09	Smithkline Beecham Plc	Pharmaceutical composition
WO2003050112A1 (en) *	2001-12-13	2003-06-19	Smithkline Beecham Plc	Toluenesulfonate hydrates of a thiazolidinedione derivative
GB0129876D0 (en) *	2001-12-13	2002-02-06	Smithkline Beecham Plc	Novel pharmaceutical
GB0129871D0 (en) *	2001-12-13	2002-02-06	Smithkline Beecham Plc	Novel pharmaceutical
GB0130509D0 (en) *	2001-12-20	2002-02-06	Smithkline Beecham Plc	Novel pharmaceutical
US7435741B2 (en)	2006-05-09	2008-10-14	Teva Pharmaceutical Industries, Ltd.	2-N{5-[[4-[2-(methyl-2-pyridinylamino) ethoxy] phenyl]methyl]-2,4-thiazolidinedione} butanedioic acid, methods of preparation and compositions with rosiglitazone maleate
ES2294980T1 (es) *	2006-05-09	2008-04-16	Teva Pharmaceutical Industries Ltd.	Acido 2-n-(5-((4-(2-(metil-2-piridinilamino)etoxi)fenil)metil)-2,4-tiazolidindiona)-butanodioico, procedimientos de preparacion y composiciones con maleato de rosiglitazona.
WO2015008234A1 (en) *	2013-07-17	2015-01-22	Glenmark Pharmaceuticals S.A.	Bicyclic heterocyclic compounds as ror gamma modulators

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ATE186724T1 (de) *	1987-09-04	1999-12-15	Beecham Group Plc	Substituierte thiazolidindionderivate
GB9218830D0 (en) *	1992-09-05	1992-10-21	Smithkline Beecham Plc	Novel compounds
WO1995021608A1 (en) *	1994-02-10	1995-08-17	Smithkline Beecham Plc	Use of insulin sensitisers for treating renal diseases
JPH11510508A (ja) *	1995-08-10	1999-09-14	ワーナー−ランバート・コンパニー	インシュリン非依存性真性糖尿病患者に投与される外来インシュリンの量を減らす方法
WO1997018811A1 (en) *	1995-11-17	1997-05-29	Warner-Lambert Company	A method of treating myotonic dystrophy
NZ314406A (en) *	1996-03-18	2000-12-22	Sankyo Co	Treatment or prophylaxis of pancreatitis with a medicament containing an insulin sensitiser including oxazoles and thiazoles
AU3552697A (en) *	1996-07-12	1998-02-09	Smithkline Beecham Plc	Novel treatment of leptine resistance

1997
- 1997-06-05 GB GBGB9711683.4A patent/GB9711683D0/en active Pending
1998
- 1998-06-02 SK SK1648-99A patent/SK164899A3/sk unknown
- 1998-06-02 CA CA002333352A patent/CA2333352A1/en not_active Abandoned
- 1998-06-02 BR BR9810405-5A patent/BR9810405A/pt not_active IP Right Cessation
- 1998-06-02 PL PL98337201A patent/PL337201A1/xx unknown
- 1998-06-02 CA CA002292629A patent/CA2292629C/en not_active Expired - Fee Related
- 1998-06-02 EA EA199901116A patent/EA002384B1/ru not_active IP Right Cessation
- 1998-06-02 WO PCT/EP1998/003478 patent/WO1998055122A1/en not_active Ceased
- 1998-06-02 TR TR2000/02790T patent/TR200002790T2/xx unknown
- 1998-06-02 KR KR19997011411A patent/KR20010013410A/ko not_active Ceased
- 1998-06-02 EP EP98932144A patent/EP0998284A1/en not_active Withdrawn
- 1998-06-02 JP JP50158799A patent/JP2001521553A/ja not_active Ceased
- 1998-06-02 AP APAP/P/1999/001696A patent/AP1214A/en active
- 1998-06-02 TR TR1999/02963T patent/TR199902963T2/xx unknown
- 1998-06-02 MX MXPA99011322A patent/MXPA99011322A/es unknown
- 1998-06-02 IL IL13307498A patent/IL133074A0/xx unknown
- 1998-06-02 CN CN98805686A patent/CN1112926C/zh not_active Expired - Lifetime
- 1998-06-02 CN CNA2003101199090A patent/CN1526391A/zh active Pending
- 1998-06-02 NZ NZ523725A patent/NZ523725A/en unknown
- 1998-06-02 AU AU82150/98A patent/AU8215098A/en not_active Abandoned
- 1998-06-02 HU HU0004070A patent/HUP0004070A3/hu unknown
- 1998-06-02 ID IDW991520A patent/ID24264A/id unknown
- 1998-06-03 DZ DZ980120A patent/DZ2510A1/xx active
- 1998-06-04 AR ARP980102649A patent/AR008198A1/es not_active Application Discontinuation
- 1998-06-04 AR ARP980102650A patent/AR015120A1/es not_active Application Discontinuation
- 1998-06-04 CO CO98031614A patent/CO4940400A1/es unknown
- 1998-06-04 UY UY25032A patent/UY25032A1/es not_active IP Right Cessation
- 1998-06-04 ZA ZA9804826A patent/ZA984826B/xx unknown
- 1998-06-04 ZA ZA9811572A patent/ZA9811572B/xx unknown
- 1998-06-05 PE PE1998000466A patent/PE78899A1/es not_active Application Discontinuation
- 1998-10-23 TW TW087117536A patent/TW570797B/zh not_active IP Right Cessation
1999
- 1999-12-02 OA OA9900267A patent/OA11306A/en unknown
- 1999-12-03 NO NO995938A patent/NO995938L/no not_active Application Discontinuation
- 1999-12-27 BG BG104048A patent/BG104048A/bg unknown
2001
- 2001-09-03 NZ NZ513922A patent/NZ513922A/xx unknown
2002
- 2002-11-05 CN CN02149972A patent/CN1430959A/zh active Pending
2004
- 2004-02-20 NO NO20040738A patent/NO20040738L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
CA2292629C (en)	2004-01-06
MXPA99011322A (es)	2004-12-02
EA002384B1 (ru)	2002-04-25
NO20040738L (no)	2000-02-02
EA199901116A1 (ru)	2000-06-26
NO995938D0 (no)	1999-12-03
NO995938L (no)	2000-02-02
AR015120A1 (es)	2001-04-18
NZ513922A (en)	2001-09-28
AR008198A1 (es)	1999-12-29
TW570797B (en)	2004-01-11
AU8215098A (en)	1998-12-21
WO1998055122A1 (en)	1998-12-10
BR9810405A (pt)	2000-08-29
JP2001521553A (ja)	2001-11-06
KR20010013410A (ko)	2001-02-26
CN1259050A (zh)	2000-07-05
NZ523725A (en)	2004-09-24
HUP0004070A2 (hu)	2002-02-28
CA2292629A1 (en)	1998-12-10
CN1526391A (zh)	2004-09-08
PL337201A1 (en)	2000-08-14
CA2333352A1 (en)	1998-12-10
GB9711683D0 (en)	1997-08-06
CN1112926C (zh)	2003-07-02
ZA984826B (en)	1999-08-03
TR200002790T2 (tr)	2001-11-21
CO4940400A1 (es)	2000-07-24
HUP0004070A3 (en)	2002-03-28
IL133074A0 (en)	2001-03-19
TR199902963T2 (xx)	2000-02-21
DZ2510A1 (fr)	2003-01-25
PE78899A1 (es)	1999-10-22
ID24264A (id)	2000-07-13
OA11306A (en)	2003-10-22
ZA9811572B (en)	1999-07-22
CN1430959A (zh)	2003-07-23
AP1214A (en)	2003-10-08
SK164899A3 (en)	2000-11-07
AP9901696A0 (en)	1999-12-31
EP0998284A1 (en)	2000-05-10
UY25032A1 (es)	1998-11-26

Publication	Publication Date	Title
CZ298469B6 (cs)	2007-10-10	Farmaceutický prostredek obsahující 5-[4-/2-(N-methyl-N-(2-pyridyl)amino)ethoxy/benzyl]thiazolidin-2,4-dion a metformin, a lécivo pro lécení diabetesmellitus
CA2292629C (en)	2004-01-06	Composition comprising 5-[4-[2-(n-methyl-n-2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione
HRP20000405A2 (en)	2000-12-31	Hydrate of 5-/4-/2-(n-methyl-n-(2-pyridil)amino) ethoxy)benzyl/thiazolidine-2,4-dione, maleic acid salt
SK179399A3 (en)	2000-11-07	Use of insulin sensitiser and an insulin
US20040180937A1 (en)	2004-09-16	Composition comprising 5-[4-[2-(N-methyl-N-2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione
BG64817B1 (bg)	2006-05-31	Комбинация от тиазолидиндион и сулфонилуреа, състав и използване
TW586926B (en)	2004-05-11	A pharmaceutical composition for the treatment of diabetes mellitus and conditions associated with diabetes mellitus in a mammal
SK179499A3 (en)	2000-11-07	The use of insulin sensitiser and alpha-glucosidase inhibitive antihyperglycaemic agent
CZ432299A3 (cs)	2000-08-16	Kompozice obsahující 5-[4-[2-(N-methyl-N-(2- pyridyI)amino)ethoxy]benzyl]thiazolidin-2,4-dion
CZ9904579A3 (cs)	2001-06-13	Léčivo pro léčbu diabetes mellitus a stavů spojených s diabetes mellitus
AU9513401A (en)	2002-01-17	Composition comprising 5-(4-(2-(N-methyl-N-2-pyridyl) amino)ethoxy)benzyl)thiazolidine-2,4-dione
MXPA99012065A (en)	2000-08-01	Treatment of diabetes with rosiglitazone and insulin
NZ518076A (en)	2004-02-27	5-[4-[2-(N-methyl-N-(2- pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione (BRL49653) for treating non-insulin dependent diabetes (NIDDM)
HU226960B1 (en)	2010-03-29	Combination of a dioxothiazolidine and metformin, and pharmaceutical compositions containing the same for the treatment of diabetes
HK1029272B (en)	2007-12-07	Treatment of diabetes with thiazolidinedione and sulphonylurea